Substituted quinazoline compounds and methods of use thereof
US10351550B2 · kind B2 · utility
27Cited by
56References
32Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 8, 2018 |
| Grant date | Jul 16, 2019 |
| Priority date | — |
| Expiry date | Mar 8, 2038 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N33/532
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds have the following structure (I): or a pharmaceutically acceptable salt, stereoisomer or prodrug thereof, wherein R, R1, R2a, R2b, R2c, A, B, L1 and E are as defined herein. Methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds and methods to modulate the activity of G12C mutant KRAS protein for treatment of disorders, such as cancer, are also provided.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.